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Abstract
Background: MicroRNAs (miRNAs) play key roles in mammalian gene expression and several
cellular processes, including differentiation, development, apoptosis and cancer pathomechanisms.
Recently the biological importance of primary cilia has been recognized in a number of human
genetic diseases. Numerous disorders are related to cilia dysfunction, including polycystic kidney
disease (PKD). Although involvement of certain genes and transcriptional networks in PKD
development has been shown, not much is known how they are regulated molecularly.
Results: Given the emerging role of miRNAs in gene expression, we explored the possibilities of
miRNA-based regulations in PKD. Here, we analyzed the simultaneous expression changes of
miRNAs and mRNAs by microarrays. 935 genes, classified into 24 functional categories, were
differentially regulated between PKD and control animals. In parallel, 30 miRNAs were differentially
regulated in PKD rats: our results suggest that several miRNAs might be involved in regulating
genetic switches in PKD. Furthermore, we describe some newly detected miRNAs, miR-31 and
miR-217, in the kidney which have not been reported previously. We determine functionally
related gene sets, or pathways to reveal the functional correlation between differentially expressed
mRNAs and miRNAs.
Conclusion: We find that the functional patterns of predicted miRNA targets and differentially
expressed mRNAs are similar. Our results suggest an important role of miRNAs in specific
pathways underlying PKD.
Background
MicroRNAs (miRNAs) are known to regulate the expres-
sion of key genes relevant to cancer and potentially other
diseases [1-3]. MiRNAs are short noncoding RNAs of
about 22 nt length that have recently been shown to play
important roles in mammalian gene expression [1,3-5].
They induce posttranscriptional gene repression by block-
ing protein translation (by binding to the 3' UTR of their
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the potential to play central roles in physiological and
pathological conditions. Recently, it has been shown that
miRNAs can also increase translation [6,7]. The physio-
logical conditions of a cell seem to affect the recruitment
of regulatory proteins, which can alter the effect of a
miRNA.
MiRNAs are transcribed as long primary transcripts (pri-
miRNAs), some of them being polycistronic, which are
processed in the cell nucleus by an enzyme called Drosha,
yielding precursor miRNAs (pre-miRNAs) that exhibit a
characteristic stem-loop sequence [8]. These are exported
into the cytosol where mature miRNAs are generated by
the RNAse Dicer, producing the small single-stranded
miRNA [8]. Translational inhibition, which seems to be
the major mode of action in animals, is performed by a
riboprotein complex called RNA-induced silencing com-
plex (RISC) consisting of the miRNA and proteins of the
argonaute family [9,10].
MiRNAs are involved in several cellular processes, includ-
ing cellular differentiation [11,12], organism develop-
ment [13,14], and apoptosis [15,16]. While all of these
are conserved in metazoans, the number of conserved
miRNAs between mammals suggests that there are addi-
tional functions only found in vertebrates [4], e.g. control-
ling hematopoietic differentiation [17]. Recent studies
provide growing evidence for the involvement of miRNAs
in cancer pathomechanisms [18-21]. However, to date
nothing is known regarding miRNAs in the context of
Polycystic Kidney Diseases.
Cilia and flagella are ancient, evolutionary conserved
organelles that project from cell surfaces to perform
diverse biological roles, including whole-cell locomotion,
movement of fluid, chemo-, mechano-, and photosensa-
tion, and sexual reproduction. The concept of ciliopathies
has helped in advancing a unifying theory of cystic kidney
diseases [22]. This theory states that the products of all
genes that are mutated in cystic kidney diseases in
humans, mice, or zebrafish are expressed in primary cilia
or centrosomes of renal epithelial cells [22].
There are numerous disorders linked to basal body and/or
cilia dysfunction, including polycystic kidney disease
(PKD), primary ciliary dyskinesia (PCD), nephronoph-
thisis (NPHP1–9) [23], Senior-Loken syndrome, Joubert
syndrome, Meckel syndrome, oral-facial-digital syn-
drome, Alström syndrome and Bardet-Biedl syndrome
[24]. These syndromes are typically associated with one or
more of the symptoms like cystic kidneys [25], retinal
degeneration and retinitis pigmentosa [16], situs inversus
[26,27], anosmia [28], respiratory problems [26], infertil-
ity [26], hydrocephalus [29], other ailments like obesity,
diabetes, liver fibrosis, hypertension, heart malforma-
tions, skeletal anomalies (e.g. polydactyly), cognitive
impairment and developmental defects such as exenceph-
aly [16,26].
Although the mechanisms of the cyst formation are not
clearly understood, they are postulated to involve
improper functioning of several pathways including cell
proliferation, apoptosis, cell polarity, and fluid secretion
[30]. Woo [31] has described apoptotic cells in glomeruli,
cyst walls, and in both cystic and non-cystic tubules of the
polycystic kidneys. Apoptotic loss of renal tissue may be
associated with the progressive deterioration of renal
function that occurs in patients with autosomal dominant
polycystic kidney disease (ADPKD). There is evidence that
genes involved in the regulation of cell proliferation, such
as p53, c-fos, cyclin D1, and c-myc may be involved in the
control of apoptosis [32]. Veis and colleagues have shown
overexpression of c-myc in human ADPKD in association
with increased levels of apoptosis and cell proliferation
[33]. It is clear that pathogenesis of PKD is very compli-
cated and involves multiple molecular pathways with
overlapping, complementary, or opposing effects. There
are several signalling pathways that have been implicated
in ciliary function [34]. The dysregulation of mitogen-acti-
vated protein kinases (MAPKs) in the cyst epithelium of
pcy (polycystic kidney disease) mice, carrying a missense
mutation in NPHP3 [35], is a downstream consequence
of disturbed renal monocilia function [36]. The proteins,
implicated in the formation of renal cysts in tuberous scle-
rosis, have been found at the ciliary base. They form a
complex that inhibits mTOR resulting in retarded cyst for-
mation in rats with PKD [37]. Cilia-mediated signalling
acts as a switch between canonical and non-canonical
Wnt signalling pathways [34].
Rats or mice have been used as common model systems
for the study of PKD. The Hannover rat, Han:Sprague-
Dawley (SPRD)-cy rat is an accepted model for human
PKD [38,39] and has been efficiently used since more
than a decade. It is an autosomal dominant model for
PKD resulting in cyst formation and slowly progressive
chronic renal failure [39]. In the current investigation, we
explore the transcriptional changes that occur in PKD and
investigate if these changes could be related to miRNAs.
We use a microarray-based approach to profile the tran-
scriptional (mRNA) changes as well as changes in the
miRNA expression patterns in PKD. We use the Han:SPRD
cy/+ rat model [39] for our current investigation. Our
results suggest several miRNAs may be involved in regu-
lating the genetic switches in PKD. Furthermore we
describe some newly detected miRNAs in the kidney.
Methods
Animals and physiological state
Inbred homozygous unaffected (+/+) and heterozygous
affected (cy/+) Han:SPRD rats exhibiting PKD were inves-Page 2 of 17
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dominant mutation that causes cystic kidneys and is an
accepted model for human PKD [40]. After approximately
40 generations of inbreeding this substrain was registered
as PKD/Mhm-cy inbred strain of rats: polycystic kidney
diseases, Mannheim, Germany hereafter designated as
PKD/Mhm. From each of the aforementioned PKD/Mhm
(cy/+) and PKD/Mhm (+/+) animals, littermates were
investigated. The animals were sacrificed by cervical dislo-
cation at day 36. On the day of sacrifice, body weight was
determined. Following dislocation, the left and right kid-
neys were immediately removed and weights were deter-
mined. Kidneys were preserved for histological analyses
and the genotypes were confirmed. Histological analysis
of pathogenesis was performed using hematoxylin-esosin
(HE) staining of the kidney section (3 μm) followed by
cyst grading under light microscope [41,42]; kidneys were
graded on 1–5 scale as previously described [41,42].
We had ethical approval to carry out this work on animals
by Regierungspraesidium Nordbaden and Internal Review
Board.
RNA isolation and Affymetrix microarray
Total RNA was extracted using TRIzol method according
to manufacturer's protocol (Invitrogen Life Technolo-
gies). cDNA synthesis was performed using the Super-
Script Choice System (Invitrogen Life Technologies,
Invitrogen Corporation) according to manufacturer's pro-
tocol. Biotin-labelled cRNA was produced using ENZO
BioArray High Yield RNA Transcript Labelling Kit. The
standard protocol from Affymetrix (Santa Clara, CA) with
3.3 μL of cDNA was used for the in vitro transcription
(IVT). Cleanup of the IVT product was done using
CHROMA SPIN-100 columns (Clontech, USA). Spectro-
photometric analysis was used for quantification of cRNA
with acceptable A260/A280 ratio of 1.9 to 2.1. After that,
the cRNA was fragmented using Affymetrix defined proto-
col. Labelled and fragmented cRNA was hybridized to
Affymetrix Rat 230_2 microarrays for 16 hrs at 45°C using
Affymetrix defined protocol. cRNA in the range of 15 μg
was used for all the 12 microarrays. Microarrays were
washed using an Affymetrix fluidics station 450 and
stained initially with streptavidin/phycoerytherin. For
each sample the signal was further enhanced by incuba-
tion with biotinylated goat anti-streptavidin followed by
a second incubation with streptavidin/phycoerytherin,
and a second round of intensities were measured. Micro-
arrays were scanned with an Affymetrix scanner controlled
by the Affymetrix Microarray Suite software. A total of 12
Affymetrix whole genome arrays (from 6 healthy and 6
diseased biological replicates) were performed.
MicroRNA microarray
Locked Nucleic Acid (LNA) based miRNA hybridization
assays were done as described by Castoldi et al. [43].
Briefly, 5 μg RNA was hybridized to a miRNA microarray
(miChip v6.0), containing probes for ~300 miRNAs,
based on LNA-modified and Tm-normalized oligonucle-
otide capture probes (miRCURY Array probes, Exiqon)
spotted onto Codelink (GE Healthcare) in multiple repli-
cates, and scanned using an Axon Scanner 4000B. Micro-
array images were analyzed using the Genepix Pro 4.0
software [43]. As for the Affymetrix whole genome arrays,
6 biologically replicated arrays, each for healthy and dis-
eased animals (total of 12 chips) were performed.
Statistical and bioinformatics analysis of microarray data
Microarray data obtained from Affymetrix chips were ana-
lyzed using SAS Micro-Array Solution version 1.3 (SAS,
USA). Normalization of raw data was performed by fitting
a mixed linear model across all arrays in the experiment.
Log2-transformed scores of all spot measures were sub-
jected to normalization. Identification of differentially
expressed genes was carried out by Mixed Model Analysis
(MMA) using ANOVA approach. A Bonferroni adjustment
for multiple testing with α ≤ 0.05 was used to calculate the
statistical significance threshold/cut-off [negative log10
(α)]. Custom CDFs version 8 (UniGene CDF files) [44]
were used for annotations. Significantly up-regulated
genes in PKD/Mhm (cy/+) animals were defined as those
with >0 log-fold-changes in expression and down-regu-
lated as those having <0 log-fold-changes in expression at
p-value < 0.05 (adjusted for multiple testing).
The raw data from miRNA chips were also normalized
and analyzed using the same modules in SAS Micro-Array
Solution version 1.3, as described above. Significantly up-
regulated miRNAs in PKD/Mhm (cy/+) animals were
defined as those with >0 log-fold-changes in expression
and down-regulated as those having <0 log-fold-changes
in expression at p-value < 0.05 (adjusted for multiple test-
ing).
Genes previously reported as targets for the significantly
regulated miRNAs, and differentially regulated in PKD,
were obtained from Argonaute [45]. In addition, targets
for the significantly regulated miRNAs, in the genes differ-
entially regulated in PKD, were predicted using two algo-
rithms: TargetScan [46] and miRanda [47]. To identify the
genes commonly predicted by both algorithms, results
were intersected using a Perl script; the intersection of Tar-
getScan and miRanda algorithms was used for further
analysis.
Identification of pathways possibly affected by miRNAs 
and their target genes in PKD
The pathways affected in PKD were determined for the sig-
nificantly regulated genes from KEGG [48], GeneOntol-
ogy (GO) [49], Biocarta http://www.biocarta.com/ and
the Molecular Signature database [50]. To check whether
significantly regulated genes are overrepresented in aPage 3 of 17
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correction for multiple testing was used. Pathways show-
ing p-value less than 0.05 were considered as significantly
enriched.
Reverse transcription and quantitative real-time PCR 
(qPCR) analysis of miRNAs
qPCR assays for miRNAs were performed using "TaqMan
MicroRNA Assays" (Applied Biosystems, USA). The
reverse transcriptase reactions were performed as per the
manufacturer's protocol. Real-time PCR was also per-
formed using a standard TaqMan PCR kit protocol on the
Applied Biosystems 7000 Sequence Detection System. 6
biological replicates were used for analysis and all the
reactions were run in quadruplicates. The comparative CT
method for relative quantitation of gene expression was
used to determine miRNA expression levels among the
normal animals and PKD/Mhm (cy/+) animals according
to manufacturer's protocol. miR-193a was used as an
endogenous control to normalize the expression levels of
targets. The miR-193a served as a good choice for endog-
enous control because its expression was almost uniform
in all the samples on the miRNA-chips (0.99 ± 0.026) and
it was not differentially regulated among the tested sam-
ples. miRNAs with ubiquitous and stable expression val-
ues are superior normalizers to other RNAs such as 5S
rRNA, U6 snRNA or total RNA [52,53]. Consistency in
expression of miR-193a across all the samples was evident
in qPCR assays (mean CT-value 29.51 ± 0.19). The signif-
icance of differences in relative expression of miRNAs
among the two groups was tested by One-way ANOVA
method in SAS version 9.1.
Results
Pathological status of PKD/Mhm(cy/+) and healthy PKD/
Mhm (+/+) animals
We used 36 day-old PKD/Mhm(cy/+) and control
(healthy) PKD/Mhm (+/+) animals to profile expression
differences in m- and mi-RNAs. At this time the disease is
still in the early stages. The Cy/+ Han:SPRD rat develops
clinically detectable PKD by 8 weeks of age as evidenced
by a doubling of kidney size and kidney failure compared
with +/+ control rats. But disease symptoms in form of
cysts can be observed using histological sectioning of the
kidneys. Using HE staining followed by cyst counting, dis-
eased kidneys can be grouped into 5 grades [41,42]. Grade
1 kidneys have occasionally small and medium-sized cysts
and sometimes small accumulations of predominantly
small cysts in up to four localizations per slide. Grade 2
kidneys have few regularly distributed small and medium-
sized cysts with up to five medium-sized cysts per visual
field, rarely large cysts (considerably larger than the size of
the glomeruli), and cysts are not detected in every visual
field. Grade 3 kidneys have several small and medium-
sized cysts (up to 10 medium-sized cysts per visual field),
few large cysts and cysts are in any visual field. A great
number of small, medium-sized and large cysts with two
or more large cysts in nearly any visual field and the occur-
rence of net-like structures that linked large cysts together
are the characteristics of grade 4. In grade 5 there is practi-
cally no normal kidney tissue visible and the histology
exhibits only large cysts and network-like structures. Six
biological replicates graded 3–4 (Figure 1).
In order to get insight into the genome-wide transcrip-
tional rearrangements during PKD, we adapted a microar-
ray based approach (Figure 2). We co-profiled the changes
in transcript (mRNA) and miRNA expressions from the
same sets of healthy and diseased kidney tissue using
Affymetrix and Exiqon arrays for mRNA and miRNAs
respectively.
Profiling miRNA expression change during PKD
In order to investigate the changes in miRNA profiles, we
examined the expression of miRNAs between kidneys of
PKD/Mhm (cy/+) and control PKD/Mhm (+/+) animals
Examples for different cyst gradings in 36 day old male PKD/Mhm ratsFigure 1
Examples for different cyst gradings in 36 day old male PKD/Mhm rats. At this age cyst grades of heterozygous 
(PKD/Mhm (cy/+)) affected kidneys are ranging between grade 3 (B) and 4(C), compared to a homozygous unaffected (healthy) 
kidney (A). Most of the animals are showing cyst grade 3. Hematoxylin/Eosin stained; Scale bar 250 μm.
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conserved between human, mouse and rat [54], therefore,
above said chips could be effectively used to profile
miRNA in our rat model. We identified 30 differentially
regulated miRNAs (Table 1), distributed in 21 different
families, at a cut-off ≥ 1.7 (negative log10 (p-value ≤ 0.05,
after Bonferroni's correction for multiple testing)). Out of
30 miRNAs, 29 were down-regulated in PKD/Mhm (cy/+)
animals and only one miRNA, miR-21, was up-regulated.
Cluster analysis of chips showed that miRNA-microarray
was able to distinguish 83.3% diseased and healthy ani-
mals (Figure 3). Interestingly, the expressions of miR-31
and miR-217 have not been previously reported in kid-
ney. We verified the changes in the expression patterns of
Schematic representation of combinatorial approach identifying miRNAs and their targetsFigure 2
Schematic representation of combinatorial approach identifying miRNAs and their targets. mRNA and miRNA 
expression profilings were analysed by Mixed Model Analysis in SAS. 935 genes were differentially regulated on Affymetrix 
chips whereas 30 miRNAs were differentially changed on Exiqon chips. Target genes for differentially expressed miRNAs were 
obtained from Argonaute as well as TargetScan and miRanda and resulting genes were overlapped with differentially expressed 
mRNAs. Functionally related gene sets or pathways, determined for differentially expressed mRNAs and predicted target 
genes of differentially expressed miRNAs, were compared and the overlap gave 36 associated gene sets, out of which 10 were 
significantly enriched pathways.
??????????????????????
????????????
????????????
?? ?????????
????????
??????????????????????????????????? ?????????????????????????? ????????
????????????
??????????????????????? ??????????????????????
??
??
?????????????????????????????????? ??????????????????????????????????
??Page 5 of 17
(page number not for citation purposes)
BMC Genomics 2008, 9:624 http://www.biomedcentral.com/1471-2164/9/624some of these miRNAs using quantitative real-time PCR
(qPCR; Figure 4). We verified the expression changes of
the only up-regulated miRNA, miR-21: in the qPCR
assays, it was 3.5 fold up-regulated in the kidney of dis-
eased animals, compared to healthy ones. In line with the
expression on the miRNA-arrays, in qPCR analysis (Figure
4), miR-31 was 3.15 fold down regulated in diseased sam-
ples compared to healthy tissue.
Microarray analysis of genes involved in PKD
To study the genetic regulation in PKD, we performed
gene expression profiling study using Affymetrix chips
(RAE230_2) on PKD/Mhm (cy/+) and control, PKD/
Mhm (+/+), rats. The arrays were analyzed by SAS Micro-
Array Solution version 1.3. A number of 1740 probe sets,
according to custom CDF version 8 [44], corresponding to
935 genes were found to be significantly regulated at a cut-
off (negative log10) of 5.5584 (Additional file 1). Several
genes strongly associated with PKD such as Clusterin
[55,56], Vimentin [56], Timp [56], Bcl2 [57], several
members of MAPK signaling [58] etc. were strongly differ-
entially regulated in expected orientations, showing the
reliability of mRNA expression profiles. Table 2 shows the
top 25 significantly up/down-regulated genes according
to the negative log10 of p-values.
In order to reveal the functional meaning of differentially
regulated genes, we analyzed the biological pathways
these genes may be involved in. We used a curated list of
162 gene sets (pathways) (Additional file 2) correspond-
ing to 1335 genes. They had been obtained from KEGG,
MSigDB, GO and Biocarta http://www.biocarta.com/ to
identify pathways of significantly regulated genes in [48-
50]. Out of 935 significantly regulated genes, only 233
genes were found in this list. These 233 genes were
involved in 100 pathways (as shown in Figure 2), which
were further categorized into 24 functional groups, based
on KEGG terminology (Additional file 3, Figure 5). Over-
representation analysis (ORA) examines the genes that
meet a selection criterion and determines if there are gene
Table 1: Significantly regulated miRNAs on Exiqon chips from SAS analysis
Name of miRNAs 
on chip
miRNA name in 
rat*
Lsmean animal 
PKD
Lsmean animal 
Control
Log Fold Change 
PKD_Ctrl
-log10(p-value) for 
log fold change of 
PKD_Ctrl
hsa-miR-21 rno-miR-21 0.80 0.24 0.56 4.50
hsa-miR-302c-star -0.63 -0.33 -0.30 3.32
hsa-miR-31 rno-mir-31 -0.47 -0.13 -0.34 3.22
hsa-miR-302c -0.76 -0.30 -0.46 3.22
hsa-miR-217 rno-mir-217 -0.74 -0.41 -0.33 3.09
mmu-miR-34b rno-mir-34b -0.59 -0.35 -0.24 3.00
hsa-miR-126-star rno-mir-126-star -0.32 -0.07 -0.25 2.98
hsa-miR-7 rno-mir-7 -0.60 -0.23 -0.37 2.92
hsa-miR-128b rno-mir-128 -0.69 -0.37 -0.32 2.92
hsa-miR-302b-star -0.53 -0.27 -0.26 2.76
hsa-miR-136 rno-mir-136 -0.70 -0.37 -0.33 2.75
hsa-miR-99a rno-mir-99a -0.40 -0.14 -0.26 2.68
hsa-miR-448 rno-mir-448 -0.55 -0.27 -0.28 2.64
mmu-miR-380-3p rno-mir-380 -0.63 -0.12 -0.51 2.62
hsa-miR-20 rno-mir-20 -0.31 -0.12 -0.19 2.58
hsa-miR-96 rno-mir-96 -0.65 -0.40 -0.26 2.57
hsa-miR-372 -0.75 -0.46 -0.29 2.55
mmu-miR-7b rno-mir-7b -0.46 -0.13 -0.34 2.48
hsa-miR-379 rno-mir-379 -0.74 -0.40 -0.34 2.47
hsa-miR-203 rno-mir-203 -0.50 -0.23 -0.27 2.34
hsa-miR-147 rno-mir-147 -0.66 -0.42 -0.23 2.16
hsa-miR-196a rno-mir-196a 0.13 0.38 -0.25 2.10
hsa-miR-335 rno-mir-335 -0.72 -0.21 -0.51 1.94
hsa-miR-216 rno-mir-216 -0.70 -0.41 -0.29 1.94
hsa-miR-128a rno-mir-128 -0.65 -0.32 -0.33 1.92
hsa-miR-30a-3p rno-mir-30a -0.15 0.03 -0.18 1.90
hsa-miR-148a -0.39 -0.27 -0.12 1.85
hsa-miR-181b rno-mir-181b -0.35 -0.14 -0.20 1.80
hsa-miR-346 rno-mir-346 -0.69 -0.39 -0.30 1.78
hsa-miR-377 rno-mir-377 -0.58 -0.35 -0.23 1.75
*miRNA probes present on Exiqon chip start with name "hsa-" and "mmu-" as shown in column 1. The miRNAs listed here are conserved in "Rat", 
shown in column 2.Page 6 of 17
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these pathways showed that 13 of them were significantly
enriched (P < 0.05) in the PKD (cy/+) animals (as shown
in Figure 2). Of those, major signal transduction signal-
ling pathways previously described [58-60] as involved in
various aspects of PKD, such as TGF-β, mTOR signalling
pathway, MAPK, calcium signalling pathway, Wnt and
JAK/STAT signalling pathways, were regulated.
Identifying miRNA-target interaction
Our miRNA-micorarray profiling revealed changes in
miRNA expression pattern, indicating that miRNAs play a
role in regulating the gene expression during PKD. We
Differential expression of miRNA in PKD and control (Ctrl) animalsFigu  3
Differential expression of miRNA in PKD and control (Ctrl) animals. Heatmap was produced using simultaneous 
clustering of rows and columns of the data matrix using complete linkage algorithm and a euclidean distance metric. Prior to 
clustering, values were transformed to zero (row-wise) mean and unit (row-wise) variance. The miRNA clustering tree is 
shown on the left and the sample clustering tree is shown on the top. The samples are clustering broadly into two groups, con-
trol (Ctrl) and PKD. The color scale shown at the right illustrates the relative expression level of the indicated miRNA across 
all samples: red denotes expression > 0 and blue denotes an expression < 0. miRNAs shown here are from miRNA microar-
rays.Page 7 of 17
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lated miRNAs to differentially regulated genes (935,
obtained from our mRNA expression experiment). We
first looked for already reported targets by comparing the
list of differentially regulated miRNAs and the genes to the
available miRNA-target interactions present in the Argo-
naute database [45]. A total of 25 genes are reported as tar-
gets of 15 miRNAs (Table 3a). But none of these miRNA-
target interactions were reported in PKD. Out of these 25
genes, 11 genes are known to affect 23 pathways that were
grouped into 11 functional categories (Figure 6a). Five
pathways, namely GnRH signaling pathway, MAPK sign-
aling pathway, Long term depression, Calcium signaling
pathway and Neuroactive ligand receptor interaction were
significantly enriched in PKD animals, as revealed by
ORA.
Secondly, we mapped the differentially regulated genes
for miRNA targets for the differentially regulated miRNAs
using two tools, TargetScan [46] and miRanda [47]. Only
commonly predicted targets for different miRNAs were
taken for further analysis. A number of 65 genes were
identified as miRNA targets, common from TargetScan as
well as miRanda (Table 3b), out of which 31 genes partic-
ipate in regulating 33 pathways, which could further be
grouped into 13 functional categories (Figure 6b). The
intersection of TargetScan and miRanda results gave target
genes for 20 miRNAs out of 30 differentially regulated
miRNAs. This shows that available prediction tools are
not yet fully optimal. Altogether, we obtained 89 target
genes differentially expressed on Affymetrix chips (Figure
2). These were associated with 36 pathways, out of which
10 were significantly enriched by ORA (Table 3a and 3b;
Figure 2).
miRNAs are generally thought to negatively regulate the
expression of their targets by mRNA degradation or by
repressing translation [61]. So if a given miRNA is down-
regulated, the expression of its target is expected to be up-
regulated. In light of this mode of miRNA action, we next
scrutinized the relationship of the expression patterns of
the differentially regulated miRNA and their targets iden-
tified in the above exercise. Eleven targets for 11 miRNAs
had expression patterns in opposite direction (Table 4),
indicating that these relationships may be functional
miRNA-target combinations in PKD. We were unable to
find a direct, down-regulated target, for miR-21.
Discussion
In the current investigation, we explore the possible
involvement of miRNAs in PKD. In a well characterized
rat model system (Han:SPRD cy/+ rat model; [39]), we
used a combinatorial approach involving data mining
and microarray analysis, to profile the miRNAs involved
in PKD. In parallel to the miRNA expression profiling, we
also describe the changes in mRNA transcript patterns in
PKD using genome-wide Affymetrix arrays. Whereas, the
gene expression arrays e.g. Affymetrix arrays have already
established themselves for measuring large-scale differen-
tial regulation of mRNAs, microarrays have recently been
developed to measure miRNA expression changes accu-
rately [43,62]. We used arrays based on LNA technology
[43]. The cluster analysis of the control and PKD miRNA-
microarrays showed tight clustering PKD samples (Figure
3). Few studies have appeared showing the use of pro-
teomics based approaches for identifying specific miRNA
targets [63-66]. Several of these studies also applied
mRNA-expression arrays to derive correlations between
the protein- and messenger- turndown. Over-expressing
miRNAs resulted in repressed targets, both at protein and
qPCR analysis of miRNAs in PKDFigure 4
qPCR analysis of miRNAs in PKD. Expression of 3 miRNAs (miR-21, 31 and 196a) significantly regualted on miRNA 
microarray was verified using qPCR assays. *** significantly different at P < 0.001.
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Table 2: Top 25 up-regulated and 25 down-regulated genes on Affymetrix chips from SAS analysis
Affymetrix_ID UniGene ID Gene_Symbol Log_fold_change (>0 = up-
regulated; <0 = down-
regulated)
-log10(p-value) for 
Estimate of 
diseased_healthy
1367581_a_at, 1396689_at Rn.8871 Spp1 2.2450 41.2288
1378015_at Rn.39658 RGD:1311996 1.9669 35.0162
1367784_a_at Rn.1780 Clu 3.3779 29.5397
1367913_at Rn.105938 Cygb 1.4106 28.3857
1381343_at, 1383222_at Rn.1708 LOC257646 0.8336 22.6443
1386996_at Rn.103179 RGD:628855 0.7756 22.4535
1388114_at Rn.103179 Mrlcb 0.7756 22.4535
1388745_at Rn.54039 RGD:1304636 0.7278 22.2871
1370992_a_at, 1371258_at Rn.98846 Fga 1.0091 21.9972
1370186_at Rn.13686 Psmb9 0.9171 21.6556
1398347_at Rn.16368 RGD:1312008 1.1720 21.2353
1368504_at, 1398816_at Rn.40177 Lamp1 0.4187 20.6298
1368168_at Rn.16933 RGD:620889 2.1632 20.4333
1387391_at Rn.10089 Cdkn1a 0.4408 20.1517
1373204_at Rn.17071 RGD1310725_predicted 1.1134 18.9746
1369956_at Rn.19927 RGD:620570 0.5636 18.7804
1385625_at, 1393240_at Rn.16151 Efemp2 1.0126 18.3754
1368207_at Rn.24997 Fxyd5 0.7122 17.9030
1371244_at Rn.2498 RGD:1307758 0.5877 17.6513
1368160_at Rn.34026 Igfbp1 1.0420 17.1419
1368821_at, 1368822_at, 
1371331_at, 1394119_at
Rn.95652 Fstl1 0.7759 17.1139
1389189_at, 1396539_at, 
1398294_at
Rn.6401 Actn1 1.4167 16.9389
1367712_at Rn.25754 Timp1 1.3548 16.9170
1387892_at Rn.2458 Tubb5 1.0106 16.8147
1367823_at, 1375144_at, 
1386940_at, 1388312_at
Rn.10161 Timp2 0.2867 16.7147
1369400_a_at, 1388044_at, 
1388063_a_at, 1398320_at
Rn.44844 Pfkfb2 -0.2293 20.3237
1370268_at Rn.44291 Kcna5 -0.2714 17.3640
1369178_a_at, 1385148_at Rn.91176 P2rx1 -0.2108 5.5590
1378419_at Rn.87496 LOC474169 -0.3129 5.5606
1369279_at Rn.81185 Dhrs9 -0.2163 5.5612
1388051_at Rn.81026 Slc26a3 -0.3637 5.5618
1368695_at Rn.11151 C4bp-ps1 -0.2888 5.5684
1369341_a_at Rn.7033 Acvrinp1 -0.1886 5.5718
1394129_at, 1396858_at Rn.7033 Acvrip1 -0.1886 5.5718
1369358_a_at Rn.37430 Hap1 -0.1699 5.5727
1387320_a_at Rn.89629 RGD:708527 -0.1887 5.5781
1367571_a_at, 1371206_a_at, 
1398322_at
Rn.118681 Igf2 -0.1007 5.5784
1371564_at Rn.103171 RGD:735157 -0.1572 5.5789
1387292_s_at, 1387991_at Rn.80837 Capn8 -0.2614 5.5793
1369253_at Rn.90021 Kremen -0.2313 5.5831
1369240_a_at Rn.10096 Avpr1b -0.2056 5.5835
1382417_at Rn.90967 RGD:1309306 -0.1498 5.5848
1369552_at Rn.81187 Samsn1 -0.2144 5.5849
1368763_at Rn.10652 Il3 -0.2808 5.5851
1369444_at Rn.21402 Cyp19a1 -0.3457 5.5866
1387582_a_at Rn.81203 Pde7b -0.2523 5.5870
1375494_a_at, 1387409_x_at Rn.10263 Nlgn3 -0.1551 5.5897
1377146_at Rn.18675 RGD:621647 -0.2512 5.5908
1387615_at Rn.44391 RGD:621843 -0.2146 5.5965
1387065_at, 1395839_at Rn.37434 Plcd4 -0.2386 5.5978
BMC Genomics 2008, 9:624 http://www.biomedcentral.com/1471-2164/9/624messenger levels: how much both processes contribute to
down-regulation of targets depends on individual
miRNA-mRNA pairs [65]. These studies show that mRNA
profiling are indeed valuable tools for studying mRNA-
miRNA interaction, although additional information on
fine-tuning of proteome-expression may be obtained by
including proteomics approaches.
Our study, profiling the changes in the mRNA transcripts
in PKD, revealed large-scale changes. Although some tran-
scription factors, such as SP1 [67], JUN and c-myc [68]
have been implicated to play a role in PKD, the magnitude
of transcriptional changes (>900 genes) suggest involve-
ment of other regulators. Moreover, the regulatory basis of
changes in the expression of transcription factors involved
in PKD remains poorly understood. On the other hand,
miRNAs have emerged recently as key regulators of gene
expression in many developmental [69,70] and disease
events [71,72]. Our miRNA study shows that changes in
gene expression during PKD also involve miRNAs.
Overrepresented miRNA regulatory pathways in PKDFigu  5
Overrepresented miRNA regulatory pathways in PKD. Fisher's exact test was used to identify significant enrichment 
for pathway annotations among predicted targets of dysregulated miRNAs and differentially expressed mRNAs in PKD. Path-
ways (from KEGG, MSigDB, Biocarta, GO) have been grouped in larger functional categories according to the KEGG annota-
tion. The pie-chart shows 22 functional categories and each pie represents a functional category with an overrepresentation of 
regulatory pathways of miRNA targets as well as mRNAs. Only pathways overlapped from the functional patterns of predicted 
miRNA targets and differentially expressed mRNAs are shown.
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Table 3: miRNAs and their targets
a: miRNAs and their previously reported targets (from Argonaute database). miRNAs and their corresponding targets are both differentially regulated during PKD.
miRNA Target Genes Pathways
miR-128 ABCB9, BTG1, DSCR1, RASD1 ABC transporters General
miR-136 GRN, PPP1R9B
miR-147 HOXA1, PTGFRN
miR-148 EGR3, SCN3A
miR-181b IGF1R, NKX6-1 Adherens junction, Maturity onset diabetes of the, Focal adhesion, **Long term depression
miR-196a ABCB9, CPB2, IRS1, MAPK10 ABC transporters General, Complement and coagulation cas, Adipocytokine signaling pathwa, Insulin 
signaling pathway, Type II diabetes mellitus, Fc epsilon RI signaling pathwa, Focal adhesion, **GnRH signaling 
pathway, **MAPK signaling pathway, Toll like receptor signaling p, Wnt signaling pathway
miR-203 SARA1
miR-20 BTG1, SARA1, YWHAB Cell cycle
miR-21 TPM1
mir-216 GNAZ **Long term depression
miR-217 RHOA Adherens junction, Axon guidance, Focal adhesion, Leukocyte transendothelial mig, Regulation of actin 
cytoskelet, TGF beta signaling pathway, T cell receptor signaling path, Tight junction, Wnt signaling pathway
miR-31 ATP2B2, DNM1L, EGR3, 
PPP1R9B, YWHAB
**Calcium signaling pathway, Cell cycle
miR-7 SLC23A2
miR-7b HRH3, NCDN, SLC23A2 **Neuroactive ligand receptor in
b: miRNAs and their targets (from TargetScan and miRanda). miRNAs and their corresponding targets are both differentially regulated during PKD.
miRNA Target Genes Pathways
miR-128 ABCB9, BTG2, CACNB2, CNR1, 
COL3A1, GLRA2, IRS1, NEK6, 
PDE7B, PTPN5, SV2A, SYT4, 
YWHAB, NR5A2, NTRK3
ABC transporters General, **MAPK signaling pathway, **Neuroactive ligand receptor in, **Cell 
Communication, **ECM receptor interaction, Focal adhesion, Adipocytokine signaling pathwa, Insulin 
signaling pathway, Type II diabetes mellitus, Purine metabolism, Cell cycle, Maturity onset diabetes of the
miR-136 KCNH7
miR-148 OTX1, YWHAB Cell cycle
miR-181b ADAMTS1, ATP2B2, CACNB2, 
CDH13, CNR1, DUSP6, EGR3, 
EPHA7, GRIK2, GRM5, GRM7, 
HOXA1, MMP14
**Calcium signaling pathway, **MAPK signaling pathway, **Neuroactive ligand receptor in, Axon guidance, 
Gap junction, **Long term depression, Long term potentiation, **GnRH signaling pathway
miR-196a ABCB9, COL3A1, EPHA7, GAS7, 
OTX1
ABC transporters General, **Cell Communication, **ECM receptor interaction, Focal adhesion, Axon 
guidance
miR-203 TGFB3 Cell cycle, **MAPK signaling pathway, TGF beta signaling pathway
miR-21 BTG2
miR-217 CLU, FN1, GRIK2, KCNH5, 
NR4A2, RAP1B
**Cell Communication, **ECM receptor interaction, Focal adhesion, Regulation of actin cytoskelet, 
**Neuroactive ligand receptor in, Leukocyte transendothelial mig, Long term potentiation, **MAPK signaling 
pathway
miR-302b* ATP2B2 **Calcium signaling pathway
miR-302c ATP2B2, CNR1, SNF1LK **Calcium signaling pathway, **Neuroactive ligand receptor in
miR-302c* ATP2B2, SNF1LK **Calcium signaling pathway
miR-30a-3p CCKBR, COLEC12, EPHA7, 
GRM7, JUN, KCNAB1, LIN7A, 
MAMDC1, PRRX1
**Calcium signaling pathway, **Neuroactive ligand receptor in, Axon guidance, B cell receptor signaling path, 
Focal adhesion, **GnRH signaling pathway, **MAPK signaling pathway, T cell receptor signaling path, Toll like 
receptor signaling p, Wnt signaling pathway
miR-346 GRM7, LTBP2 **Neuroactive ligand receptor in
miR-372 ATP2B2, NR4A2, SNF1LK, RET, 
SLC11A2
**Calcium signaling pathway
miR-448 COLEC12, DNM3, GRIK2, IGF1R, 
IL12B, KCNH7, KCNIP4, SCN3A, 
SCN5A
**Neuroactive ligand receptor in, Adherens junction, Focal adhesion, **Long term depression, **Cytokine 
cytokine receptor int, **Jak STAT signaling pathway, Toll like receptor signaling p, **Type I diabetes mellitus
miR-34b BTG2, CALCR, DLL1, MYRIP **Neuroactive ligand receptor in, Notch signaling pathway
miR-380-3p BCL2L1 Amyotrophic lateral sclerosis, Apoptosis, **Jak STAT signaling pathway, Neurodegenerative Disorders
miR-7b EGR3
**Significantly overrepresented pathways from ORA
BMC Genomics 2008, 9:624 http://www.biomedcentral.com/1471-2164/9/624When we compared the mRNA and miRNA profiles, dif-
ferentially regulated in PKD, with Argonaute (a compre-
hensive database on miRNAs; [45,71]), there were few
genes reported as miRNA target like tropomyosin 1, alpha
(TPM1) as a target of miR-21, the beta polypeptide of
tyrosine 3-monooxygenase/tryptophan 5-monooxygen-
ase activation protein (YWHAB), regulatory subunit 9B of
protein phosphatase 1 (PPP1R9B), early growth response
3 (EGR3) and dynamin 1-like (DNM1L) as targets of miR-
31, plysia ras-related homolog A2 (RHOA) as targets of
miR-217, etc. (Table 3a). But none of these genes had pre-
viously been associated with PKD. Over-representation
analysis showed the enrichment of five pathways namely,
GnRH signaling pathway, MAPK signaling pathway, Long
term depression, Calcium signaling pathway and Neu-
roactive ligand receptor interaction. The comparison of
differentially regulated genes/miRNAs to Argonaute data-
base indicates that previously known miRNA-target inter-
actions (Table 3a) could play important roles in PKD.
Parallel profiling of the transcripts as well as miRNAs on
the same set of samples gives us insight into potential
interactions between miRNAs and differentially expressed
targets in PKD. This parallel profiling allowed us to scruti-
nize for the negative expression patterns for the miRNA-
target relation at a given time point (Table 4). A negative
relationship of the expression patterns between miRNA
and its target mRNA is an important parameter for deter-
mining their interactions because miRNA, in general, are
regarded as negative regulators of their targets.
Microarray analysis of miRNAs revealed down regulation
of 29 out of 30 differentially regulated miRNAs, which
corresponded to increased expression of several genes
related to pathways upregulated during PKD. To further
uncover the functional correlation between differentially
expressed mRNAs and miRNAs, we determined function-
ally related gene sets, or pathways. The differentially regu-
lated mRNAs were associated with 24 functional
categories, which included several enriched pathways
important to renal diseases. Previous studies of cystic kid-
neys implicated several pathways thought to contribute to
the pathogenesis of renal cysts' formation like mTOR sig-
nalling, MAPK (Mitogen-Activated Protein Kinase) signal-
ling, Wnt signalling, and the TGF-β (Transforming
Growth Factor-β) pathway.
MAPKs play important roles in the cell by transmitting
extracellular signals from the cell membrane to the
nucleus [73]. MAPKs are activated by various stimuli,
influencing cell proliferation, differentiation, and apopto-
sis. Aberrant regulation of MAPKs and other signalling
pathways has been reported to be consistent with altered
regulation of cell proliferation and differentiation
observed in renal cystic disease [58]. Sustained activation
of MAPKs in kidney epithelial cells inhibits normal epi-
thelial phenotype and formation of adherens junctions
[74]. The expression of genes involved in MAPK signalling
pathway like MAP3K1, JUN, and MYC was significantly
higher in the PKD animals, indicating the activation of
MAPK signalling pathway.
Wnt signalling is essential for renal development. Recent
research has revealed an unexpected intersection between
Wnt signalling and PKD [59]. It has been reported that
canonical Wnt signalling seemed mandatory for early
renal development, but persistent β-catenin signalling
seemed to trigger cyst formation at later developmental
stages [59]. Components of the Wnt signalling pathway
like FZD2, JUN, MYC, and RHOA were significantly
upregulated in our PKD animals.
TGF-β promotes renal cell hypertrophy and stimulates
extracellular matrix accumulation in several renal dis-
eases, including diabetic nephropathy [75] and PKD [76].
It activates the inhibitors of the proteases e.g. tissue inhib-
itors of metalloproteinases and plasminogen activator
inhibitor 1 [77]. TGF-β 1, TGF-β 2 and TGF-β 3 were con-
sistently upregulated in PKD-affected animals. The expres-
sion of extracellular matrix components, such as collagen
triple helix repeat containing 1 (CTHRC1), and fibronec-
tin 1 (FN1) was significantly higher in animals with PKD.
One of the integrins, integrin beta 1 (ITGB1) was upregu-
lated. Therefore, there was a clear activation of the TGF-β
signaling pathway in the PKD animals with a significant
increase of the synthesis of the extracellular matrix com-
ponents and inhibition of the proteases that digest this
matrix. Recently Kato et al. showed that miRNA miR-192
has been associated with TGF-β pathway in diabetic kid-
ney glomeruli [78]. Its implication in PKD has not been
shown, though.
We could not find negative co-relations between the pre-
dicted targets of the only up-regulated miRNA, miR-21,
whose expression was verified by qPCR analysis too. All
the predicted targets were up-regulated. It should be noted
that alternate action mechanisms for miRNAs also exist.
The action of miRNAs may not to be reflected on the level
of their target mRNAs as they are believed to block or
attenuate further translation of mRNAs to protein. In such
conditions, miRNAs will exert their regulatory role on the
level of translation. Moreover, a new mode of action
where the miRNAs act as positive regulators has also been
defined recently [7]. Depending upon the state of a cell, a
miRNA can act as positive or negative regulator [7].
The specific cellular pathways that were found to be asso-
ciated with dysregulated miRNAs or differentially
expressed transcripts in PKD can be used to shape some
initial hypotheses on how alteration of miRNA expressionPage 12 of 17
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Overrepresented miRNA regulatory pathways in PKD (for target genes obtained from Argonaute)Figu  6
Overrepresented miRNA regulatory pathways in PKD (for target genes obtained from Argonaute). 6A. The 
pie-chart shows overrepresented pathways for the target genes obtained from Argonaute. Each pie denotes an overrepresen-
tation of regulatory pathways of predicted targets of dysregulated miRNA as well as differentially expressed mRNAs in PKD; 
and also the percentage of genes overrepresented in the pathway. 6B. Similarly here the pie-chart shows overrepresented 
pathways for the predicted miRNA targets obtained from TargetScan as well as miRanda.
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BMC Genomics 2008, 9:624 http://www.biomedcentral.com/1471-2164/9/624may be directly involved in the disease. Furthermore, the
functional correlation between the differentially
expressed mRNAs and miRNAs in PKD revealed a tight
posttranscriptional regulation network at both mRNA and
protein level.
Conclusion
While this work establishes a multi-tiered approach for
investigation of miRNA mode of genetic regulations of
PKD, the results await further investigation. PKD is an
important disease as 8–10% of all patients on renal
Table 4: Selected inverse miRNA-target relation identified
miRNA Target Genes Pathways Identified by Log fold change miRNA Log fold change gene
hsa-miR-128a COL3A1 **Cell Communication, 
**ECM receptor interaction, 
Focal adhesion
TargetScan miRanda -0.32881 1.36067
hsa-miR-128a YWHAB Cell cycle TargetScan miRanda -0.32881 0.39416
hsa-miR-128b COL3A1 **Cell Communication, 
**ECM receptor interaction, 
Focal adhesion
TargetScan miRanda -0.32151 1.36067
hsa-miR-128b YWHAB Cell cycle TargetScan miRanda -0.32151 0.39416
hsa-miR-148a YWHAB Cell cycle TargetScan miRanda -0.11883 0.39416
hsa-miR-181b IGF1R Adherens junction, Focal 
adhesion, **Long term 
depression
Argonaute -0.20269 0.39429
hsa-miR-181b MMP14 **GnRH signaling pathway TargetScan miRanda -0.20269 0.63365
hsa-miR-181b DUSP6 **MAPK signaling pathway TargetScan miRanda -0.20269 0.66781
hsa-miR-181b GRIK2 **Neuroactive ligand 
receptor in
TargetScan miRanda -0.20269 0.54227
hsa-miR-196a COL3A1 **Cell Communication, 
**ECM receptor interaction, 
Focal adhesion
TargetScan miRanda -0.24597 1.36067
hsa-miR-203 TGFB3 Cell cycle, **MAPK signaling 
pathway, TGF beta signaling 
pathway
TargetScan miRanda -0.26753 0.38630
hsa-miR-20a YWHAB Cell cycle Argonaute -0.18897 0.39416
hsa-miR-217 RHOA Adherens junction, Axon 
guidance, Focal adhesion, 
Leukocyte transendothelial 
mig, Regulation of actin 
cytoskelet, T cell receptor 
signaling path, TGF beta 
signaling pathway, Tight 
junction, Wnt signaling 
pathway
Argonaute -0.32869 0.56512
hsa-miR-217 FN1 **Cell Communication, 
**ECM receptor interaction, 
Focal adhesion, Regulation of 
actin cytoskelet
TargetScan miRanda -0.32869 1.15979
hsa-miR-217 RAP1B Focal adhesion, Leukocyte 
transendothelial mig, Long 
term potentiation, **MAPK 
signaling pathway
TargetScan miRanda -0.32869 0.40226
hsa-miR-217 GRIK2 **Neuroactive ligand 
receptor in
TargetScan miRanda -0.32869 0.54227
hsa-miR-30a-3p JUN B cell receptor signaling path, 
Focal adhesion, **GnRH 
signaling pathway, **MAPK 
signaling pathway, T cell 
receptor signaling path, Toll 
like receptor signaling p, 
Wnt signaling pathway
TargetScan miRanda -0.18488 0.64628
hsa-miR-31 YWHAB Cell cycle Argonaute -0.33805 0.39416
hsa-miR-448 IGF1R Adherens junction, Focal 
adhesion, **Long term 
depression
TargetScan miRanda -0.28453 0.39429
hsa-miR-448 GRIK2 **Neuroactive ligand 
receptor in
TargetScan miRanda -0.28453 0.54227Page 14 of 17
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plantation, suffer from PKD [79]. The molecular compo-
nents have just started to become apparent, and we add
another layer of regulators, namely miRNAs. We predict
that several of the differentially regulated genes are
miRNA targets and miR-21, miR-31, miR-128, miR-147
and miR-217 may be the important players in such inter-
action. It is interesting to note that miR-31 and miR-217
have not been previously reported in kidney. miR-21 has
been reported in kidney [45] but its function has yet not
been established. It has been speculated in previous stud-
ies that a single miRNA could target more than hundred
genes and one gene could be the target of several miRNAs
[61,80]. Knockout and over-expression studies will pro-
vide further insight into the regulatory interaction
between these miRNAs and their targets in order to prop-
erly understand PKD development and design new thera-
peutic measures.
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